Kumar Amit, Cannon Christopher P
Department of Hospital Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Mayo Clin Proc. 2009 Nov;84(11):1021-36. doi: 10.1016/S0025-6196(11)60674-5.
At the most severe end of the spectrum of acute coronary syndromes is ST-segment elevation myocardial infarction (STEMI), which usually occurs when a fibrin-rich thrombus completely occludes an epicardial coronary artery. The diagnosis of STEMI is based on clinical characteristics and persistent ST-segment elevation as demonstrated by 12-lead electrocardiography. Patients with STEMI should undergo rapid assessment for reperfusion therapy, and a reperfusion strategy should be implemented promptly after the patient's contact with the health care system. Two methods are currently available for establishing timely coronary reperfusion: primary percutaneous coronary intervention and fibrinolytic therapy. Percutaneous coronary intervention is the preferred method but is not always available. Antiplatelet agents and anticoagulants are critical adjuncts to reperfusion. This article summarizes the current evidence-based guidelines for the diagnosis and management of STEMI. This summary is followed by a brief discussion of the role of noninvasive stress testing in the assessment of patients with acute coronary syndrome and their selection for coronary revascularization.
急性冠状动脉综合征最严重的一端是ST段抬高型心肌梗死(STEMI),它通常发生在富含纤维蛋白的血栓完全阻塞心外膜冠状动脉时。STEMI的诊断基于临床特征以及12导联心电图显示的持续性ST段抬高。STEMI患者应接受快速再灌注治疗评估,并且在患者与医疗系统接触后应立即实施再灌注策略。目前有两种方法可用于及时建立冠状动脉再灌注:直接经皮冠状动脉介入治疗和溶栓治疗。经皮冠状动脉介入治疗是首选方法,但并非总是可行。抗血小板药物和抗凝剂是再灌注的关键辅助药物。本文总结了目前基于证据的STEMI诊断和管理指南。随后将简要讨论无创负荷试验在急性冠状动脉综合征患者评估及其冠状动脉血运重建选择中的作用。